Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Somewhat Bullish +50

Moderna Inc (MRNA) Q1 2026 Earnings Call Highlights: Strategic Growth Amidst Legal Challenges

📈 Moderna reported Q1 2026 revenue of $400 million, representing a $300 million year-over-year increase driven by strategic partnerships like those with the UK government.

💰 The company posted a net loss of $1.3 billion on a GAAP basis, while excluding a one-time litigation settlement, the adjusted loss was $0.5 billion.

💵 Moderna holds a strong balance sheet with $7.5 billion in cash and investments at the end of Q1 2026.

📉 R&D expenses decreased by 24% year-over-year to $649 million, while SG&A expenses fell 18% to $173 million.

⚖️ A significant portion of costs was driven by a litigation settlement with Arbutus and Genevant totaling $878 million included in the cost of sales.

📅 The full $950 million litigation settlement payment is scheduled for due in Q3 2026.

🌍 Approximately 80% of revenue comes from international markets, with the remaining 20% from the United States.

⚠️ Management issued guidance expecting up to 10% revenue growth for the full year 2026 but noted a potential slowdown in Q2 projections.

💉 Moderna achieved a regulatory milestone with the EU approval of mCOMBRIAX, the first flu plus COVID combo vaccine.

🦠 Spikevax also received approval in the European Union, expected to drive growth in that market starting in 2027.

🏥 The company advanced its oncology pipeline by initiating a Phase 3 clinical trial for intismeran in non-small cell lung cancer with a focus on early-stage disease.

💬 Management clarified that the first quarter's UK delivery was for the spring campaign, with an additional fall campaign planned for Q3 and Q4.

🔬 An interim analysis for the Phase 3 trial of intismeran in adjuvant melanoma is expected to be conducted in 2026 based on event accrual.

⚖️ The CFO stated that a potential additional liability of $1.3 billion related to the 1498 case is not recorded as probable, with resolution possibly occurring in late 2027 or 2028.

📉 Analysts warned of potential future declines in COVID vaccination rates which could negatively impact revenue growth going forward.

Bullish Signals
  • Revenue grew $300 million year-over-year to $400 million in Q1 2026, demonstrating strong commercial traction.
  • R&D expenses decreased by 24% and SG&A expenses dropped 18%, indicating improved operational efficiency despite the net loss.
  • Moderna maintains a robust cash position with $7.5 billion in cash and investments, providing ample liquidity for growth initiatives.
  • The company achieved a strategic milestone with mCOMBRIAX approval in the European Union, opening new market opportunities.
  • Revenue guidance anticipates up to 10% growth for 2026, signaling continued expansion beyond the current quarter.
  • Moderna secured approvals for Spikevax in the European Union, driving expected growth in the EU market for 2027.
  • The Phase 3 clinical trial for intismeran in non-small cell lung cancer has officially begun, diversifying the pipeline into oncology.
  • Management remains optimistic about future outcomes, noting they are "confident" regarding the litigation appeal and see no need to record a charge yet.
  • A second UK delivery campaign is planned for the fall, potentially creating a double year of deliveries and boosting revenue in Q3/Q4.
  • Early-stage disease focus with monotherapy safety profiles looks promising for preventing relapse, opening avenues for potential cures.
  • Phase 2 studies for RCC and muscle invasive bladder cancer are fully enrolled, positioning these assets to move quickly toward registrational studies if data is favorable.
Risk Factors
  • The company reported a significant net loss of $1.3 billion on a GAAP basis in Q1 2026, primarily driven by an $878 million litigation settlement.
  • Moderna faces potential additional liability of up to $1.3 billion if it does not prevail in its appeal regarding the litigation settlement with Arbutus and Genevant.
  • A significant portion of Cost of Sales ($955 million) is attributed to litigation settlements rather than direct product costs, potentially distorting profitability metrics.
  • GuruFocus has detected 4 Warning Signs for MRNA, indicating potential undisclosed risks or financial vulnerabilities.
  • Revenue guidance for Q2 2026 ranges between $50 million and $100 million, representing a substantial deceleration compared to the $400 million generated in Q1 2026.
  • The company anticipates potential future declines in COVID vaccination rates, which poses a direct threat to revenue growth forecasts.
  • Revenue is heavily skewed geographically, with 80% coming from international markets and only 20% from the United States, increasing exposure to foreign exchange and regulatory risks abroad.
  • The resolution timeline for the $1.3 billion litigation charge could extend into late 2027 or 2028, creating prolonged uncertainty over future cash flows.
Full Analysis
Moderna Inc (MRNA) reported Q1 2026 revenue of $400 million, representing a significant $300 million year-over-year increase, with costs of sales rising to $955 million primarily due to an $878 million litigation settlement related to Arbutus and Genevant. On a GAAP basis, the company recorded a net loss of $1.3 billion for the quarter, though excluding the litigation payment, the loss stood at $0.5 billion. The company maintained a robust cash position with $7.5 billion in cash and investments as of the end of Q1 2026. Despite these financial results, revenue guidance indicates potential deceleration, with expectations for up to 10% growth in 2026 overall but a second-quarter forecast between $50 million and $100 million. Geographically, Moderna's revenue mix showed a strong international presence at 80%, compared to 20% from the United States during the quarter. A major milestone was the approval of mCOMBRIAX, the first flu plus COVID combo vaccine, in the European Union, alongside maintained availability of Spikevax which is expected to drive EU market growth in 2027. Strategic advancements were highlighted in oncology, where Moderna initiated a Phase 3 clinical trial for intismeran in non-small cell lung cancer with a focus on early-stage disease. The company also noted the strategy of pursuing intismeran both as a monotherapy and in combination with KEYTRUDA to achieve potential cures in high-risk Stage 1 small cell lung cancer by intervening early to prevent relapse. On the legal front, Moderna disclosed a pending litigation settlement of $950 million due in Q3 2026 but also faces potential additional liability up to $1.3 billion regarding a 1498 matter if the appeal is unsuccessful. Management, including President Stephen Hoge and CFO James Mock, expressed confidence in avoiding charges on the latter case, anticipating resolution in late 2027 or 2028. Operational updates included plans for a second UK delivery campaign for spring boosters in the fall, with interim analysis expected for the adjuvant melanoma Phase 3 trial in 2026 based on event accrual. The company acknowledged the potential for future declines in COVID vaccination rates that could impact revenue growth. GuruFocus has flagged four warning signs for MRNA, noting the challenges associated with high cash burn against strategic investment and legal contingencies.